Evolus (NASDAQ:EOLS) Earns “Buy” Rating from BTIG Research

Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating reaffirmed by equities researchers at BTIG Research in a research report issued on Wednesday,Benzinga reports. They currently have a $13.00 target price on the stock. BTIG Research’s target price points to a potential upside of 129.68% from the stock’s current price.

A number of other equities research analysts also recently weighed in on the stock. Mizuho set a $15.00 price target on shares of Evolus in a research note on Wednesday, February 4th. Stifel Nicolaus lowered their target price on Evolus from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Tuesday, January 13th. Needham & Company LLC reissued a “hold” rating on shares of Evolus in a research report on Wednesday, December 24th. Wall Street Zen upgraded Evolus from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, HC Wainwright cut their price target on Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Evolus currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Evolus Stock Up 1.3%

EOLS opened at $5.66 on Wednesday. The stock’s 50 day moving average price is $5.06 and its two-hundred day moving average price is $6.23. The firm has a market capitalization of $368.24 million, a P/E ratio of -6.99 and a beta of 1.02. Evolus has a 12-month low of $4.09 and a 12-month high of $14.28.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported $0.00 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.09). The firm had revenue of $90.30 million during the quarter, compared to the consensus estimate of $89.58 million. As a group, analysts anticipate that Evolus will post -0.61 earnings per share for the current year.

Insider Transactions at Evolus

In other Evolus news, insider David Moatazedi sold 10,539 shares of the firm’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $7.15, for a total value of $75,353.85. Following the transaction, the insider directly owned 354,388 shares of the company’s stock, valued at $2,533,874.20. This trade represents a 2.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.90% of the stock is owned by insiders.

Institutional Trading of Evolus

Large investors have recently made changes to their positions in the company. Rice Hall James & Associates LLC increased its stake in shares of Evolus by 17.4% in the 3rd quarter. Rice Hall James & Associates LLC now owns 1,168,886 shares of the company’s stock valued at $7,177,000 after purchasing an additional 172,846 shares during the last quarter. Frazier Life Sciences Management L.P. bought a new stake in shares of Evolus during the 2nd quarter worth $22,431,000. Frontier Capital Management Co. LLC boosted its stake in Evolus by 37.9% in the second quarter. Frontier Capital Management Co. LLC now owns 1,664,828 shares of the company’s stock valued at $15,333,000 after buying an additional 457,533 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new position in Evolus in the second quarter valued at about $434,000. Finally, Squarepoint Ops LLC grew its position in Evolus by 830.2% in the second quarter. Squarepoint Ops LLC now owns 105,797 shares of the company’s stock valued at $974,000 after acquiring an additional 94,423 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

Key Evolus News

Here are the key news stories impacting Evolus this week:

• Positive Sentiment: Q4 revenue beat and market rally: Evolus reported Q4 revenue slightly above estimates and the stock saw a strong intraday rally following the results, signaling investor confidence in demand for its aesthetic products. Evolus posts record rally after Q4 beat
• Positive Sentiment: Raised 2026 revenue guidance: Management released FY‑2026 revenue guidance of $327M–$337M, above consensus (~$316M), and signaled expanding international presence and product portfolio—this lifts revenue growth expectations for 2026. Evolus outlines 2026 revenue guidance
• Positive Sentiment: Analyst support: BTIG reaffirmed a Buy rating and set a $13 price target, implying substantial upside vs. current levels and likely supporting positive sentiment among growth/value investors. BTIG reaffirms buy
• Neutral Sentiment: EPS miss vs. revenue beat: Evolus reported EPS of $0.00, missing the consensus of $0.09, but revenue of $90.3M slightly topped estimates — a mixed result that leaves profitability questions but supports top‑line momentum. Q4 earnings details
• Neutral Sentiment: Earnings call/transcript available: Management commentary from the Q4 call and transcript provide more context on margins, capex, and international expansion — useful for assessing sustainability of guidance. Earnings call transcript
• Neutral Sentiment: Short interest data flagged as zero: A March short‑interest entry shows 0 shares short (likely a reporting/data anomaly); current days‑to‑cover reads 0.0 — no clear bearish pressure indicated by this report. (Data may be unreliable.)
• Negative Sentiment: New data‑privacy compliance risk disclosed: Evolus added a data privacy/compliance risk to its filings, which could raise potential regulatory, operational, and remediation costs if issues arise. Investors should monitor any follow‑up disclosures. Data privacy risk report

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.